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Abstract
Introduction: Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-called borderline
elevation of mPAP (BoPAP)—a condition thought to represent early-stage pulmonary arterial vasculopathy. Based on
the DETECT study, this post-hoc analysis examined patient characteristics of systemic sclerosis (SSc) patients with normal
mPAP, BoPAP and elevated mPAP, fulfilling pulmonary arterial hypertension (PAH) criteria.
Methods: Adult patients with a duration of SSc more than 3 years, a diffusing capacity of the lung for carbon
monoxide less than 60% predicted, and no previous diagnosis of any form of pulmonary hypertension (PH) underwent
screening tests followed by right heart catheterization. Subjects were divided into three groups: normal mPAP, BoPAP,
and PAH. Exploratory comparative and binary logistic regression analyses were performed for the BoPAP versus normal
mPAP and PAH versus BoPAP groups.
Results: Of 244 patients evaluated, 148 (60%) had normal mPAP, 36 (15%) had BoPAP, and 60 (25%) had definite PAH.
Univariable logistic regression (ULR) showed the mean tricuspid regurgitation velocity in patients with BoPAP to be
intermediate between normal mPAP and PAH. In the ULR analyses BoPAP versus normal mPAP and PAH versus BoPAP,
the statistically significant predictors were, amongst others: demographic, clinical, pulmonary function,
echocardiographic and hemodynamic variables.
Conclusions: In this exploratory post-hoc analysis of the DETECT study population patients with BoPAP could be
distinguished from patients with normal mPAP and PAH, and it appears that BoPAP may be an intermediate stage
on the continuum between normal PA pressures and PAH.
Introduction
Systemic sclerosis (SSc, scleroderma) is an autoimmune
connective tissue disorder characterized by inflammation,
fibrosis and vasculopathy. Pulmonary arterial hypertension
(PAH) is a leading cause of death in SSc [1,2]. Based on
registry data, modern treatment has improved two-year
survival estimates of SSc-associated PAH (SSc-PAH) from
40% [3] to 58% [4], a clear improvement which, however,
lags gains seen in other forms of PAH [5-7]. Screening for
SSc-PAH is capable of identifying earlier stages of the dis-
ease, resulting in earlier intervention that may improve
survival [8]. Thus, early diagnosis and treatment of SSc-
PAH is of paramount importance [9,10].
The DETECT study was a multi-center study that sys-
tematically evaluated 466 SSc patients at increased risk for
development of SSc-PAH [11]. DETECT was the first SSc-
PAH detection study to evaluate all subjects with right
heart catheterization (RHC), the gold standard test for the
diagnosis of PAH [9]. Detailed demographic, clinical,
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echocardiographic, serologic and functional testing data
were also collected.
Measurements in healthy individuals show a normal
mean pulmonary arterial pressure (mPAP) to be 14 ±
3.3 mmHg [12], with 2 SD extending the normal range up
to 20.6 mm Hg. The consensus definition of PAH requires
mPAP ≥25 mmHg and pulmonary artery wedge pressure
(PAWP) of ≤15 mmHg [9,13]. Thus, a borderline range of
mPAPs exists between 21 and 24 mm Hg that may repre-
sent an early, milder stage of pulmonary vasculopathy in
those at high risk of developing PAH [13-15]. This concept
is especially relevant in connective tissue diseases (CTD),
such as SSc, where progressive vasculopathy is highly
prevalent and may be an important distinction from idio-
pathic PAH [13]. The objective of this post-hoc analysis
was to compare the demographics and clinical features of
patients with normal PAP, borderline mPAP (BoPAP), and
elevated PAP (PAH) in a large international cohort of pa-
tients with SSc who participated in the DETECT study.
The identification of characteristics specific to SSc patients
with BoPAP would facilitate future investigations into the
natural history of this condition, and provide insights into
the proportion of patients who develop PAH.
Methods
Study design
Our study was conducted in accordance with the Declar-
ation of Helsinki and its amendments, followed the Inter-
national Conference on Harmonization Guideline for Good
Clinical Practice, and was approved by local institutional re-
view boards/ethics committees (a complete list is included
as Additional file 1). RHC and echocardiography protocols
were standardized and conducted systematically, and
serum laboratory testing as well as data management were
performed centrally. Data quality was monitored rigor-
ously. All patients provided written informed consent. Pa-
tients were eligible for inclusion in DETECT if they were
aged ≥18 years and had: 1) a definite diagnosis of SSc [16]
of >3 years’ duration from first non-Raynaud’s symptom;
2) a diffusing capacity of the lung for carbon monoxide
(DLCO) <60% of predicted; 3) a forced vital capacity
(FVC) ≥40% of predicted; and 4) not had pulmonary
hypertension confirmed by RHC prior to enrolment.
Current analysis population
Patients were included in the current analysis if they had:
1) a pulmonary artery wedge pressure (PAWP) ≤15 mmHg
by RHC; 2) no significant interstitial lung disease (ILD; de-
fined as FVC <60% or FVC between 60 and 70% with
moderate-to-severe fibrosis on high resolution computed
tomography); 3) no systemic hypertension (stage-I hyper-
tension defined as systolic blood pressure ≥140 mmHg or
diastolic blood pressure ≥90) [17]; and 4) no left atrial en-
largement (defined as 3.9 cm for women and 4.1 cm for
men) [18]. DETECT screened 646 SSc patients, and en-
rolled 488 SSc patients with 466 who underwent RHC. A
total of 222 of 466 were excluded from the present ana-
lysis due to: 1) a pulmonary artery wedge pressure
(PAWP) >15 mmHg or significant ILD (138 patients), and
2) an enlarged left atrium or stage-I or greater hyperten-
sion (84 patients). Eligible patients comprise the PAP ana-
lysis set and were categorized into three PAP groups for
analysis, based on the mPAP by RHC: 1) normal mPAP
(<21 mmHg); 2) BoPAP (mPAP 21 to 24 mmHg); and 3)
PAH (mPAP ≥25 mmHg). Analysis of variables was per-
formed using these three PAP groups.
Data collection and analysis
The DETECT study collected 112 variables, collated into
four groups: 1) demographic and clinical parameters (68
variables); 2) serum tests (13 variables); 3) electrocardi-
ography (ECG) (3 variables); and 4) echocardiography
(28 variables). In the present study, variables were se-
lected for further analysis based on a review of numer-
ical descriptive differences between the three groups, as
well as input from the authors on feasibility of the vari-
ables and their clinical relevance to PAH. Two additional
variables were computed: 1) the transpulmonary gradient
(TPG) which is the difference between mPAP and left atrial
pressure (estimated by the PAWP); and 2) the diastolic
wedge gradient (DWG) which is the difference between
diastolic PAP and left atrial pressure (estimated by the
PAWP). The selected variables were described using sum-
mary statistics: sample size, mean, SD, median, upper and
lower quartiles, minimum and maximum for quantitative
data and frequencies (counts and percentages) for qualita-
tive and categorical data. The distributions of the variables
were compared using non-parametric tests: Wilcoxon
rank-sum and chi-square/Fisher’s exact test for continuous
and categorical data, respectively. Univariable logistic re-
gression (ULR) analysis was performed using BoPAP versus
normal mPAP and PAH versus BoPAP as binary outcomes
in separate models. The odds ratio (OR) and 95% CI for
each variable was calculated and statistical significance was
examined by the Wald chi-square test. A Forest plot was
constructed to display the odds ratios and the 95% CI for
13 variables in the BoPAP versus normal mPAP and PAH
versus BoPAP groups. Variables were selected for the plot if
they met the statistical significance criteria or had potential
clinical utility as screening tests for BoPAP and PAH. RHC
hemodynamics were used for exploratory purposes only, as
they were part of the group definitions.
Results
Among the 244 SSc patients included in the PAP ana-
lysis set, 60% (n = 148) had a normal mPAP, 15% (n = 36)
had BoPAP and 25% (n = 60) had an elevated mPAP
(PAH) (Figure 1).
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Baseline characteristics of patients with normal mPAP,
BoPAP and PAH
Statistically significant differences between the BoPAP
and other groups were found in clinical, serologic, echo-
cardiographic, and invasive hemodynamic parameters,
including World Health Organization functional class
(WHO FC) (PAH versus BoPAP), presence of peripheral
edema (BoPAP versus normal mPAP), presence of telan-
giectasias (PAH versus BoPAP), ratio of FVC percent pre-
dicted/DLCO percent predicted (PAH versus BoPAP), TLC
percent predicted (BoPAP versus normal mPAP), presence
of anti-centromere antibodies (PAH versus BoPAP), log10
NT-proBNP (BoPAP versus normal mPAP), serum urate
(PAH versus BoPAP), left atrium diameter (BoPAP versus
normal mPAP, tricuspid annular plane systolic excursion
(TAPSE, PAH versus BoPAP) and TR velocity (BoPAP ver-
sus both normal PAP and PAH; Table 1). Differences in the
exploratory comparison of hemodynamic variables (PAWP,
TPG, DWG and pulmonary vascular resistance (PVR))
were also noted.
Univariable logistic regression analysis
BoPAP versus normal PAP
As shown in Table 2 and Figure 2, ULR models of SSc
patients with BoPAP versus normal mPAP identified
the following variables as being statistically significant
predictors of BoPAP (P <0.05): older age, presence of
peripheral edema, a higher log10 NT-proBNP, greater
left atrium diameter, and greater tricuspid regurgitation
(TR) velocity. Of note, 6-minute walk distance was not
statistically different.
The RHC variables PAWP, TPG and PVR (which de-
fined the groups) were all statistically significant, though
DWG was not.
PAH versus BoPAP
ULR models of SSc patients with PAH versus BoPAP iden-
tified the following variables as being statistically signifi-
cant (P <0.05) predictors of PAH: higher WHO FC (III or
IV), diffuse versus limited disease subtype, the presence of
telangiectasias, higher FVC percent predicted/DLCO per-
cent predicted ratio, presence of anti-centromere anti-
bodies, higher serum urate, a lower TAPSE and a higher
TR velocity. As was the case with the BoPAP versus normal
PAP analysis, 6-minute walk distance was not statistically
different. As expected, the PAH group had a higher TPG, a
higher DWG, and a higher PVR (Table 2 and Figure 2). Of
note, the PAWP was not significantly different between
these groups.
Discussion
Expert consensus opinion from the recent 5th World
Symposium on Pulmonary Hypertension acknowledges
that a borderline mPAP between 21 and 24 mmHg in
SSc patients is associated with ‘a high risk of future de-
velopment of manifest PAHʼ, and recommends careful
follow up of these patients [13]. In our current study of
a large, well-defined, high-risk SSc cohort we identified
clinical and laboratory features that differentiate the
BoPAP group from groups with normal mPAP and PAH.
Our study provides a crucial first step towards the devel-
opment of future longitudinal studies of BoPAP, as we
RHC analysis set 
(n=466) 
PAWP > 15 mmHg or 
Significant ILD (n=138) 
Enlarged left atrium or 
systemic hypertension 
(n=84) 
Normal  
mPAP < 21 mmHg 
(n=148) 
BoPAP
mPAP 21-24 mmHg 
(n=36) 
PAH 
mPAP  25 mmHg 
(n=60) 
RHC analysis set 
(n=244) 
Figure 1 Patient disposition. This study focuses on the differences between the normal mean pulmonary arterial pressure (mPAP), borderline
pulmonary arterial pressure (BoPAP) and pulmonary arterial hypertension (PAH) subgroups of the DETECT study. ILD, interstitial lung disease;
PAWP, pulmonary artery wedge pressure; RHC, right heart catheterization.
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Table 1 Baseline characteristics of patients with normal mPAP, BoPAP and PAH
Patient groups (N =244) P-value
Variable Normal mPAP
(N =148)
BoPAP
(N =36)
PAH
(N =60)
BoPAP versus
normal mPAP
PAH versus
BoPAP
Demographic and clinical parameters
Age, years, Na 148 36 59
Mean ± SD 54.3 ± 12.0 58.4 ± 9.5 61.6 ± 9.7
Median, Q1 to Q3 55.0, 46.0 to 63.5 58.5, 52.5 to 63.5 62.0, 56.0 to 68.0
Minimum, maximum 26.0, 78.0 43.0, 80.0 33.0, 80.0
Gender, n 148 36 60
Male, n (%) 18 (12.2) 6 (16.7) 12 (20.0)
Female, n (%) 130 (87.8) 30 (83.3) 48 (80.0)
WHO FC, N 139 34 60 <0.05
I/II, n (%) 127 (91.4) 28 (82.4) 37 (61.7)
III/IV, n (%) 12 (8.6) 6 (17.6) 23 (38.3)
6-minute walk distance, N 108 27 48
Mean ± SD 422.4 ± 110.4 397.4 ± 102.3 391.4 ± 109.8
Median, Q1 to Q3 432.5, 364.5 to 502.0 414.5, 341.0 to 472.0 395.0, 318.0 to 460.5
SSc disease duration (years), N 147 36 60
Mean ± SD 11.0 ± 8.0 10.0 ± 5.0 14.0 ± 12.0
Median, Q1 to Q3 8.0, 5.0 to 13.0 9.0, 6.0 to 15.0 11.0, 6.0 to 16.0
SSc subtype, N 146 36 59
Limited, n (%) 90 (61.6) 20 (55.6) 44 (74.6)
Diffuse, n (%) 45 (30.8) 13 (36.1) 10 (16.9)
Overlap/mixed CTD, n (%) 11 (7.5) 3 (8.3) 5 (8.5)
Presence of peripheral edema, n/N (%) 8/147 (5.4) 7/36 (19.4) 11/60 (18.3) <0.01
Presence of telangiectasias, n/N (%) 108/148 (73.0) 22/36 (61.1) 52/60 (86.7) <0.005
FVC % predicted, N 148 36 60
Mean ± SD 92.5 ± 17.6 88.7 ± 14.5 92.0 ± 19.7
Median, Q1-Q3 91.9, 79.9 to 102.7 87.1, 80.0 to 96.5 89.5, 77.2 to 102.5
FVC % predicted /DLCO % predicted, N 148 36 60 <0.01
Mean ± SD 1.9 ± 0.4 1.9 ± 0.4 2.3 ± 0.7
Median, Q1 to Q3 1.8, 1.5 to 2.1 2.0, 1.5 to 2.2 2.2, 1.8 to 2.5
TLC % predicted, N 127 28 54 <0.05
Mean ± SD 92.8 ± 21.9 84.8 ± 14.4 88.1 ± 21.6
Median, Q1 to Q3 92.5, 80.0 to 106.0 83.0, 74.0 to 95.0 87.3, 78.0 to 100.3
Serum laboratory tests
Presence of anti-centromere antibodies <0.05
n/N (%) 49/141 (34.8) 10/34 (29.4) 30/56 (53.6)
Log10 NT-proBNP (pg/ml), N 141 34 56 <0.05
Mean ± SD 2.0 ± 0.5 2.2 ± 0.5 2.4 ± 0.5
Median, Q1 to Q3 2.1, 1.7 to 2.3 2.2, 1.9 to 2.5 2.3, 2.0 to 2.8
Serum urate, mg/100 ml, N 141 34 56 <0.01
Mean ± SD 4.7 ± 1.4 4.7 ± 1.3 5.6 ± 1.4
Median, Q1 to Q3 4.4, 3.7 to 5.3 4.5, 3.7 to 5.4 5.6, 4.6 to 6.5
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provide a panel of variables that can be tested to deter-
mine their prognostic utility.
Formalized early detection of SSc-PAH has been shown
to identify milder forms of the disease, resulting in oppor-
tunities for earlier management [8,19]. As algorithms and
practice guidelines are developed to improve early detec-
tion of SSc-PAH, it is likely that referrals for RHC will in-
crease (in DETECT the rate increased from 40% to 62%).
The increase in RHCs will likely result in more patients
identified with both PAH and BoPAP. The finding of
BoPAP is significant, as a number of recent studies have
shown an association between BoPAP and worse clinical
outcomes [14,15,20]. Thus, further characterization of
BoPAP is important. In the current study we identify sig-
nificant differences in clinical, serologic, echocardiographic
and hemodynamic parameters useful in differentiating
BoPAP from normal PAP and PAH from BoPAP groups.
A number of recent studies have shown an associ-
ation between BoPAP and worse clinical outcomes.
One small study compared SSc patients with mPAPs >17
Table 1 Baseline characteristics of patients with normal mPAP, BoPAP and PAH (Continued)
Log10 estimated GFR 141 34 55
1.9 ± 0.1 1.9 ± 0.1 1.9 ± 0.1
1.9, 1.9 to 2.0 1.9, 1.8 to 2.0 1.9, 1.8 to 2.0
Echocardiography
Left atrium diameter, mm, N 148 36 60 <0.001
Mean ± SD 30.2 ± 5.1 33.9 ± 3.6 31.8 ± 5.4
Median, Q1 to Q3 31.0, 27.8 to 34.0 33.5, 31.0 to 37.0 32.0, 30.0 to 36.0
Right atrium area, cm2, N 142 33 58 <0.05
Mean ± SD 12.8 ± 4.7 14.7 ± 5.9 16.8 ± 5.8
Median, Q1 to Q3 12.0, 10.0 to 14.3 12.4, 10.5 to 18.0 15.8, 13.4 to 20.0
TAPSE (mm), N 138 33 53
Mean ± SD 23.2 ± 4.3 23.8 ± 5.1 21.1 ± 4.3
Median, Q1 to Q3 23.7, 20.4 to 26.0 23.0, 20.0 to 27.0 20.8, 19.0 to 23.0
TR velocity (m/s), N 140 35 58 <0.001 <0.05
Mean ± SD 2.3 ± 0.4 2.7 ± 0.3 3.0 ± 0.7
Median, Q1 to Q3 2.3, 2.2 to 2.6 2.7, 2.5 to 2.9 2.9, 2.5 to 3.5
Electrocardiography
Presence of right axis deviation, n/N (%) 2/138 (1.4) 1/30 (3.3) 8/58 (13.8)
Right heart catheterization
PAWP, mmHg, N 148 36 60 <0.001
Mean ± SD 7.7 ± 3.3 10.8 ± 3.0 9.9 ± 3.3
Median, Q1 to Q3 8.0, 5.0 to 10.0 11.0, 9.0 to 13.0 10.5, 7.5 to 12.5
TPG, mmHg, N 148 36 60 <0.001 <0.001
Mean ± SD 7.9 ± 2.7 11.6 ± 2.8 22.3 ± 9.7
Median, Q1 to Q3 7.0, 6.0 to 10.0 11.0, 10.0 to 13.0 20.0, 15.0 to 28.0
DWG, mmHg, N 148 36 60 <0.001
Mean ± SD 1.8 ± 2.7 3.0 ± 5.4 10.7 ± 8.1
Median, Q1 to Q3 1.0, 0.0 to 3.0 2.0, 0.5 to 5.0 8.0, 5.0 to 17.0
PVR, dyn.sec/cm5, N 148 36 60 <0.001 <0.001
Mean ± SD 128.0 ± 50.8 179.8 ± 58.7 375.8 ± 217.0
Median, Q1 to Q3 121.5, 91.3 to 153.9 170.3, 147.8 to 187.8 295.5, 236.0 to 419.1
aN for each variable represents the number of patients with available data. Statistical tests were Wilcoxon rank-sum for continuous data and chi-square/Fisher’s
exact for categorical data. ‘These variables were analysed for completeness, but it should be borne in mind that they are part of the definition of the analysis
groups. BoPAP, borderline pulmonary arterial pressure; CTD, connective tissue disease; DLCO, diffusing capacity of carbon monoxide; DWG, diastolic wedge gradient;
FVC, forced vital capacity; GFR, glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAWP, pulmonary
artery wedge pressure; PVR, pulmonary vascular resistance; Q, quartile; SSc, systemic sclerosis; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity;
TPG, transpulmonary gradient; TR, tricuspid regurgitation; WHO FC, World Health Organization functional class.
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but <25 mmHg (group mean of 20 ± 2 mmHg) to those
with mPAPs ≤17 mmHg (group mean 14 ± 2 mmHg), and
found the former group to be associated with both shorter
mean 6-minute walk distances (396 ± 71 meters versus
488 ± 77 meters, P <0.005) and lower mean percent pre-
dicted peak oxygen consumption (VO2) values (76 ± 11%
versus 90 ± 24%, P = 0.05) [20]. The PHAROS registry in-
cluded 206 SSc patients at increased risk for PAH who
underwent RHC [21]. After excluding patients with signifi-
cant interstitial lung disease, a comparison of SSc patients
with normal mPAP (group median 16 mmHg) and border-
line mPAP (group median 23 mmHg) showed the latter
group to have significantly higher right ventricular systolic
pressures on echocardiogram, higher pulmonary vascular
resistance and a higher transpulmonary gradient [14].
Follow-up data involving 24 PHAROS patients who
Table 2 Univariable logistic regression analysis of patients with BoPAP versus normal PAP and those with PAH
versus BoPAP
Variable Odds ratios (95% confidence interval) P-value
BoPAP versus normal mPAP PAH versus BoPAP BoPAP versus normal mPAP PAH versus BoPAP
Demographic and clinical parameters
Age, years 1.03 (1.00, 1.07) 1.04 (0.99, 1.08)
Gender, female versus male 0.69 (0.25, 1.89) 0.80 (0.27, 2.36)
WHO FC, III/IV versus I/II 2.27 (0.78, 6.56) 2.90 (1.04, 8.08) <0.05
6-minute walk distance 1.00 (0.99, 1.00) 1.00 (1.00, 1.00)
SSc disease duration, years 0.99 (0.94, 1.04) 1.05 (1.00, 1.11)
SSc disease subtype <0.05
dcSSc versus lcSSc 1.30 (0.59, 2.85) 0.35 (0.13, 0.93)
Overlap/mixed CTD versus lcSSc 1.23 (0.31, 4.81) 0.76 (0.17, 3.48)
Presence of telangiectasias 0.58 (0.27, 1.25) 4.13 (1.52, 11.26) <0.01
Presence of peripheral edema 4.19 (1.41, 12.46) 0.93 (0.32, 2.67) <0.05
FVC predicted 0.99 (0.97, 1.01) 1.01 (0.99, 1.04)
FVC % predicted /DLCO % predicted 1.24 (0.54, 2.82) 3.41 (1.36, 8.54) <0.01
TLC % predicted 0.98 (0.96, 1.00) 1.01 (0.99, 1.04)
Serum laboratory
Presence of anti-centromere antibodies 0.78 (0.35, 1.77) 2.77 (1.12, 6.85) <0.05
Log10 NT-proBNP, pg/ml 2.65 (1.17, 5.98) 1.69 (0.71, 4.05) <0.05
Serum urate, mg/100 ml 1.01 (0.76, 1.33) 1.73 (1.20, 2.48) <0.01
Log10 estimated GFR 0.54 (0.03, 9.44) 0.04 (0.00, 1.77)
Echocardiography
Left atrium diameter, mm 1.22 (1.10, 1.35) 0.89 (0.80, 1.00) <0.001 <0.05
Right atrium area, cm2 1.07 (1.00, 1.14) 1.07 (0.99, 1.17)
TAPSE, mm 1.03 (0.94, 1.12) 0.88 (0.80, 0.98) <0.05
TR velocity, m/s 25.10 (6.07, 103.74) 3.15 (1.30, 7.67) <0.0001 <0.05
Electrocardiography
Right axis deviation 2.35 (0.21, 26.74) 4.64 (0.55, 38.99)
Right heart catheterization
PAWP, mmHg 1.39 (1.21, 1.61) 0.91 (0.79, 1.04) <0.0001
TPG, mmHg 1.57 (1.33, 1.85) 1.72 (1.35, 2.19) <0.0001 <0.0001
DWG, mmHg 1.10 (0.99, 1.21) 1.27 (1.12, 1.44) <0.0005
PVR, dyn.sec/cm5 1.01 (1.01, 1.02) 1.03 (1.01, 1.04) <0.0001 <0.0001
BoPAP, borderline pulmonary arterial pressure; CTD, connective tissue disease; dcSSc, diffuse cutaneous SSc; DLCO, diffusing capacity of carbon monoxide; DWG,
diastolic wedge gradient; FVC, forced vital capacity; GFR, glomerular filtration rate; lcSSc, limited cutaneous SSc; NT-proBNP, N-terminal pro-brain natriuretic
peptide; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; SSc, systemic sclerosis; TAPSE,
tricuspid annular plane systolic excursion; TLC, total lung capacity; TPG, transpulmonary gradient; TR, tricuspid regurgitation; WHO FC, World Health Organization
functional class.
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underwent repeat RHC at a later date showed that 32% of
patients with normal mPAP and 55% of patients with bor-
derline mPAP developed resting PH (P-value not signifi-
cant) 14.92 ± 9.23 and 12.19 ± 6.82 months after the first
RHC, respectively [14]. Another analysis compared the
outcomes of SSc patients with mPAP ≤20 mmHg to those
with mPAPs of 21 to 24 mmHg [15]. Within 228 patients
without ILD, 142 had normal mPAP and 86 had mPAP of
21 to 24 mmHg. Clinically indicated repeat RHCs were
performed in 38 patients from each group and the hazard
ratio for PAH diagnosis on the subsequent RHC for the
borderline mPAP group compared to the normal mPAP
group was 3.7 (95% CI 1.7, 8.0, P <0.001). Within the bor-
derline mPAP group, 18.5% (95% CI 8.3, 28.7) developed
PAH within 3 years, and 27.1% (95% CI 13.9, 40.3) devel-
oped PAH within 5 years [15].
In the current study we identified significant differences
in clinical, serologic, echocardiographic and hemodynamic
parameters useful in differentiating BoPAP from normal
PAP and PAH from BoPAP groups. Across both
comparisons, TR velocity was the variable most strongly
associated with BoPAP (versus normal mPAP) and PAH
(versus BoPAP).
Our analysis also identified additional variables cap-
able of differentiating BoPAP from the PAH group:
WHO functional class, SSc subtype, presence of telangiec-
tasias, ratio of % predicted FVC/percent predicted DLCO,
anti-centromere antibodies, and serum urate concentra-
tion. Some of these variables (telangiectasia [22], FVC/
DLCO [22], anti-centromere antibodies [22-24], and
serum urate [25]) have been useful in predicting SSc-PAH
in other studies.
Invasive pressure measurements including TPG and
DWG were explored, as these measurements have been
addressed in other studies of BoPAP. Elevations in these
gradients (≥12 mmHg and ≥5, respectively) [26] are be-
lieved consistent with pulmonary vascular disease, and
thus, help separate individuals with PAH from those with
pulmonary venous hypertension. As described previously
[15], the TPG in our study was capable of separating the
*Categorical variables: *1 = III/IV vs. I/II, *2 = presence vs. absence, *3 = yes vs. no 
Groups: A = normal PAP, B = BoPAP, C = PAH 
Odds Ratio 
OR (95% CI) n_A/n_B/n_C 
Laboratory Tests
Lung Function Tests
Echocardiography
Demographic & Clinical Characteristics
WHO FC (I/II, III/IV)                                      *1  
WHO FC (I/II, III/IV)                                      *1  
Current/past telangiectasias                             *2  
Current/past telangiectasias                             *2  
Presence of peripheral edema                          *3 
Presence of peripheral edema                          *3 
ACA antibody                                                  *2 
ACA antibody                                                  *2 
Log 10 of NTproBNP (pg/mL) 
Log 10 of NTproBNP (pg/mL) 
Sodium urate (mg/100 mL) 
Sodium urate (mg/100 mL) 
FVC (% predicted)/DLCO ratio 
FVC (% predicted)/DLCO ratio 
Left atrium diameter (mm) 
Left atrium diameter (mm) 
TAPSE (mm) 
TR velocity (m/s) 
TR velocity (m/s) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) 
(B vs. A) 
(C vs. B) TAPSE (mm) 
(B vs. A) 
(C vs. B) 
1 10 100 
Figure 2 Forest plot of odds ratios from univariable logistic regression analysis. ACA antibody, anti-centromere antibody; BoPAP, borderline
pulmonary arterial pressure; DLCO, diffusing capacity of carbon monoxide; FVC, forced vital capacity; NT-proBNP, N-terminal pro-brain natriuretic
peptide; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; WHO FC, World Health Organization functional class; TLC, total
lung capacity; TR, tricuspid regurgitation.
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BoPAP group from the normal PAP and PAH groups. We
also show the DWG to be useful in differentiating the
BoPAP group from the PAH group, and it has the added
benefit of being able to differentiate PAH from post-
capillary PH [26]. Though not in the abnormal range, the
mean TPG and DWG measurements for the BoPAP group
were intermediate between the normal PAP and PAH
groups, perhaps suggesting that a subset of SSc patients
with BoPAP may have early pulmonary vasculopathy.
In the present study we excluded patients with overt
pulmonary venous hypertension based upon the finding
of a PAWP >15 mmHg by RHC. It is important to ac-
knowledge that occult pulmonary venous hypertension
(OPVH) due to left heart disease may have been present
in a proportion of patients who underwent a RHC while
in a state of volume depletion, and were thus found to
have underestimated left-heart filling pressures [27]. One
study involving patients with scleroderma found that 6
out of 24 patients who originally met the criteria for
PAH by RHC were subsequently diagnosed with OPVH
after a fluid challenge [28]. As a fluid challenge was not
included in our RHC study protocol, we minimized the
likelihood of including patients with OPVH by excluding
individuals with conditions commonly associated with
OPVH: stage I or greater systemic hypertension and/or
abnormally enlarged left atrium. Future BoPAP studies
should consider the use of evocative maneuvers such as
fluid challenge or exercise in order to identify patients
with OPVH.
Our study has significant strengths. Ours is the first
BoPAP study to mandate a diagnostic RHC in all sub-
jects, allowing us to assign individuals into groups (nor-
mal mPAP, BoPAP and PAH) based on rigorous,
objective criteria. Standardization of the study protocol
and centralization of serum laboratory testing and data
management assured homogeneity. In addition, it is the
largest, most complete cohort of patients evaluated for
SSc-PAH, providing us a sufficient sample size to con-
duct our analyses.
Our study has important limitations. Results are cross-
sectional, so longitudinal follow up to determine the inci-
dence of PAH in the BoPAP group over time was not de-
termined. Our inclusion criteria included a DLCO <60%
to enrich for a higher likelihood of PAH. Thus, the groups
analyzed in our study represent a high-risk SSc group, and
may not be representative of the general SSc population.
Future studies are needed in order to expand our findings
into the general SSc population. Our study was not de-
signed to compare and model relationships involving the
BoPAP sub-group; thus, multivariable logistic regression
for this post-hoc sub-analysis could be misleading, and
was not performed. In addition, the three sub-groups ana-
lyzed (normal mPAP, BoPAP and PAH) were defined using
mPAP (a continuous variable). Various pairwise sub-
groups using binary logistic regression may provide a differ-
ent set of predictive covariables for each multiple regression
model that may be inaccurate.
Conclusion
In conclusion, our study identifies clinical, echocardio-
graphic, hemodynamic, pulmonary function, and serologic
variables that allow SSc patients with BoPAP to be differ-
entiated from SSc patients with normal mPAPs and PAH.
Future longitudinal studies designed to reassess patients
with BoPAP at pre-designated time points would be the
ideal means of validating the prognostic value of our find-
ings. Such studies would allow further characterization of
the natural history of BoPAP, including the rate and fre-
quency of conversion to pre-capillary or post-capillary PH.
Our exploratory analyses of hemodynamic data suggest
that the TPG and DWG should continue to be evaluated
as potential predictors for the development of PAH in the
SSc population.
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